Esophageal

Global Capsule Endoscopy Market Research Report 2023: Disease Type, Product, End Use, & Region Insights and Forecasts with Potential Impact of COVID-19 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 3, 2024
Biotechnology, Medical Devices, Other Health, Health, Health Technology, Patient, Endoscopy, Pain, Risk, Stomach, Artificial intelligence, Esophageal, Crohn's disease, Inflammatory bowel disease, Colorectal cancer, Prevalence, Bleeding, Hospital, Capsule endoscopy, COVID-19, Food, Esophagus, Growth, Diagnosis, Safety, Employment, Life, Medical imaging

The "Global Capsule Endoscopy Market (by Disease Type, Product, End Use, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Capsule Endoscopy Market (by Disease Type, Product, End Use, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The global capsule endoscopy market is expected to reach US$559.59 million in 2023, growing at a CAGR of 8.64% during the forecast period.
  • The range of applications for capsule endoscopy systems, including those for colon disease, small bowel disease, and esophageal illness, has increased due to technological developments.
  • Global Capsule Endoscopy Market Players: Financial Comparison
    Global Capsule Endoscopy Market Players: R&D Expenses Comparison

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

Retrieved on: 
Tuesday, December 12, 2023
Identification, Esophageal, Biomedical Research, Risk, Esophagus, Patient, Data analysis, Extrapyramidal system, Triage, Barrett's esophagus, Physician, Archive, Registry, Publication, Medical imaging, Nursing, Lucid, Endoscopy

NEW YORK, Dec. 12, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that three manuscripts providing interim results from the Prospective REView of Esophageal Precancer DetectioN in AT-Risk Patients (PREVENT) Registry, the CLinical Utility of EsoGuard (CLUE) study, and full data from the San Antonio Firefighter study, have been published—the first peer-reviewed publications demonstrating real-world clinical utility of Lucid's EsoGuard® Esophageal DNA test to detect esophageal precancer.

Key Points: 
  • Real-World Experience and Clinical Utility of EsoGuard® – Interim Data from the Lucid Registry .
  • Interim analysis of 409 of 517 enrolled patients with complete clinical utility data in the PREVENT and PREVENT-FF registries of patients undergoing EsoGuard testing by Lucid personnel.
  • "These clinical utility studies, encompassing over 1,000 patients, clearly demonstrate that prescribing physicians are properly leveraging EsoGuard results to guide their medical decision making," said Victoria T. Lee, M.D.
  • "These outstanding clinical utility results complement existing clinical validity data on EsoGuard's unprecedented precancer detection performance.

Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection

Retrieved on: 
Tuesday, October 31, 2023
Patient, Triage, Manuscript, Endoscopy, MedRxiv, Physician, Registry, Research, Esophageal, Real, Firefighter, Health, DNA, Medical imaging, Pharmaceutical industry, Lucid

NEW YORK, Oct. 31, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced two longitudinal clinical registries which are collecting real-world clinical utility and clinical validity data on EsoGuard® Esophageal DNA testing for the detection of esophageal precancer. The Prospective REView of Esophageal Precancer DetectioN in AT-Risk Patients (PREVENT) Registry collects data on EsoGuard testing in the general at-risk population, while the PREVENT-FF Registry focuses exclusively on at-risk firefighters. The Company released positive clinical utility data from an initial combined analysis of patients from both registries.

Key Points: 
  • The Prospective REView of Esophageal Precancer DetectioN in AT-Risk Patients (PREVENT) Registry collects data on EsoGuard testing in the general at-risk population, while the PREVENT-FF Registry focuses exclusively on at-risk firefighters.
  • The PREVENT Registry prospectively enrolls patients with well-established esophageal precancer risk-factors referred by a physician to Lucid for EsoGuard testing.
  • Lucid clinical personnel perform esophageal cell collection using the EsoCheck® Cell Collection Device and Lucid's CLIA-certified laboratory then performs the EsoGuard test on the sample.
  • The PREVENT-FF Registry prospectively enrolls firefighters with additional esophageal precancer risk factors referred for EsoGuard testing who participate in one of Lucid's #CheckYourFoodTube Precancer Testing Events.

ProPhase Labs Announces Data Presentation for its BE-Smart Esophageal Cancer Test 

Retrieved on: 
Monday, March 13, 2023
Disease, USCAP, Cell, HIV disease progression rates, Clinical professor, GERD, Esophageal cancer, Esophageal, Barrett's esophagus, Genomics, Mayo Clinic, Patient, Pathology, Gastroesophageal reflux disease, Marie Cassidy, Incidence, CPT, Metastasis, United States and Canadian Academy of Pathology, Cancer, Science, Prophase, Medical imaging

Garden City, NY, March 13, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be giving a data presentation at the United States and Canadian Academy of Pathology (USCAP), which is being held March 11 – 16, 2023, at the Ernest N. Morial Convention Center in New Orleans, LA.

Key Points: 
  • The Director of Norton Thoracic Institute, Dr. Sumeet Mittal, Dr. Catherine Hagen of the Mayo Clinic, Dr. Sheeno Thyparambil of mProbe Inc. and Dr. Joe Abdo, scientific advisor to ProPhase Labs, serve as co-authors of the study.
  • Dr. Andrew Cannon, an anatomic and clinical pathology resident at the Mayo Clinic serves as first author and will be giving the presentation to attendees of USCAP on Tuesday, March 14th.
  • The majority of these patients are diagnosed with gastroesophageal reflux disease (GERD) and Barrett's esophagus before their cancer is detected.
  • Four out of five esophageal cancer patients still present to their oncologist in the advanced stages when the disease is no longer curable.

FundamentalVR Announces Leading Experts in Machine Learning and Robotic Surgery Join Advisory Board

Retrieved on: 
Tuesday, February 14, 2023
Stomach, Prostate, DO, Fundamental, Esophageal, Houston, VR, Augmented reality, CMR Surgical, Diagnosis, Hiatal hernia, CMR, Staab, Vein, Enteric nervous system, Esophagus, University, Robotics, Artificial intelligence, Gastroesophageal reflux disease, Houston Methodist Hospital, Partnership, Education, Innovation, Swedish Health Services, Testicular cancer, Machine learning, Providence St. Joseph Health, KOL, Virtual reality, GERD, AR, Medical device, 3D printing, Nursing, DRS, MD

Together, the five experts will help expand the company's Fundamental Surgery platform, enhancing its robotic and precision simulation capabilities.

Key Points: 
  • Together, the five experts will help expand the company's Fundamental Surgery platform, enhancing its robotic and precision simulation capabilities.
  • The valuable additions to the advisory board will help FundamentalVR expand its offering in robotic surgery, such as the solution created for CMR Surgical (CMR) in 2022.
  • Alongside Dr. Houghton, FundamentalVR welcomes Dr. Philip Woodworth, MD, an advanced ex-military surgeon and advocate for VR, fluorescent visualization, and robotic surgery.
  • "As we continue to invest in our Fundamental Surgery platform, machine learning and robotic surgery are key strategic areas of focus to further enhance the platform's skills transfer abilities and VR environment.

CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities

Retrieved on: 
Thursday, January 5, 2023
Melanoma, Therapeutic index, Anemia, Protein, RNA transfection, Research, APC, Astellas Pharma, Camptothecin, Platinum, Diarrhea, HIV disease progression rates, Immunotherapy, PR, Colorectal cancer, Amgen, Nausea, Cancer, Patient, Tumor microenvironment, Bristol Myers Squibb, Ipilimumab, Infection, Cytokine, Degenerative disease, BMS, Febrile neutropenia, Regeneron Pharmaceuticals, ADC, Safety, Fatigue, Therapy, Webcast, IND, Triple-negative breast cancer, Neutropenia, Esophageal, Toxic leukoencephalopathy, ESMO, SD, Vaccine, Nivolumab, CR, Control, Epithelial cell adhesion molecule, Trae tha Truth, Pharmaceutical industry, Oil, Moderna, HNSCC, TCB

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced its 2023 company priorities and provided a pipeline update which included anticipated milestones for 2023, recent progress and achievements in its wholly owned and collaboration pipeline, and a data update for the Phase 2, CX-2029 cohort expansion study. The company will host a call with investors today to review the CX-2029 cohort expansion study data and potential key pipeline events for 2023.

Key Points: 
  • The company plans to rapidly advance this potentially best-in-class program towards clinical evaluation with an IND filing targeted for the second half of 2023.
  • The company anticipates filing an IND for this novel ADC in the second half of 2023.
  • CytomX enters 2023 in a strong strategic position and with significant momentum in its pipeline.
  • CytomX management will host a conference call and a simultaneous webcast today, January 5th 2023 at 5 p.m.

Insights on the Capsule Endoscopy Global Market to 2027 - Featuring CapsoVision, Check-Cap, AnX Robotica and Shangxian Minimal Invasive Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 4, 2023
Health, Biotechnology, Inflammatory bowel disease, Hospital, Endoscopy, Capsule endoscopy, Esophageal, Diagnosis, Crohn's disease, Medical imaging

By Product: According to the report, the global capsule endoscopy market is segmented into two product: Systems and Capsule Endoscopes.

Key Points: 
  • By Product: According to the report, the global capsule endoscopy market is segmented into two product: Systems and Capsule Endoscopes.
  • By Disease Type: According to the report, the global capsule endoscopy market is segmented into three disease type: Small Bowel, Esophageal and Colon.
  • By End User: The report splits the global capsule endoscopy market into three end users: Hospitals, Ambulatory Surgery Centers and Other End-Users.
  • While the US continues to be a prominent region of North America capsule endoscopy market, accounting to the growing preference for minimally invasive surgeries and technological advancements.

Global Capsule Endoscopy Market: Analysis By Disease Type, By Product, By End User, By Region Size & Forecast with Impact Analysis of COVID-19 and Forecast up to 2027

Retrieved on: 
Tuesday, December 20, 2022
Inflammatory bowel disease, Capsule endoscopy, Endoscopy, Crohn's disease, Esophageal, Growth, COVID-19, Diagnosis, Life, Diabetes, Artificial intelligence, Stomach, Colorectal cancer, Hospital, Esophagus, Pain, Prevalence, Ageing, Degenerative disease, Conditional sentence, Capsule, MI, Cancer, Medical imaging, Animal

View original content:https://www.prnewswire.com/news-releases/global-capsule-endoscopy-market...

Key Points: 
  • In 2021, the global capsule endoscopy market was valued at US$474.12 million, and is probable to reach US$779.52 million by 2027.
  • The capsule endoscopy market is projected to grow at a CAGR of 8.64%, during the forecast period of 2022-2027.
  • By Product: According to the report, the global capsule endoscopy market is segmented into two product: Systems and Capsule Endoscopes.
  • Global Capsule Endoscopy Market Dynamics:
    Growth Drivers: Increasing geriatric population supported the development of the capsule endoscopy market.

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

Retrieved on: 
Thursday, December 1, 2022
Other Health, Research, General Health, Oncology, Biometrics, Genetics, Clinical Trials, Science, Cardiology, Biotechnology, Other Science, Health, Lucid, Cell, Gene, Risk, Security (finance), LDT, NGS, Methylation, Incidence, Conference, Cyclin A1, Patient, Therapy, Laboratory developed test, VIM, Obesity, FDA, COVID-19, American College of Gastroenterology, EAC, Diagnosis, American College, DNA, Physician, Annual report, Anesthesia, Male, Research, Interception, Esophageal, Science Translational Medicine, Esophageal cancer, GERD, CCNA1, American Gastroenterological Association, Death, CE marking, Medical imaging, Pharmaceutical industry, Part Two, Cancer, Vimentin

Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that Suman M. Verma, M.D., Ph.D., Lucids Chief Scientific Officer, presented real-world data on its EsoCheck Cell Collection Device (EsoCheck) at the American Association for Cancer Researchs (AACR) Special Conference: Precision Prevention, Early Detection, and Interception of Cancer.

Key Points: 
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that Suman M. Verma, M.D., Ph.D., Lucids Chief Scientific Officer, presented real-world data on its EsoCheck Cell Collection Device (EsoCheck) at the American Association for Cancer Researchs (AACR) Special Conference: Precision Prevention, Early Detection, and Interception of Cancer.
  • Millions of patients with GERD are at risk of developing esophageal precancer and a highly lethal form of esophageal cancer (EAC).
  • Over 80% of EAC patients die within five years of diagnosis, making it the second most lethal cancer in the U.S.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).

United States Esophageal Cancer Pipeline Market Analysis and Competitive Landscape Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 2, 2022
Health, General Health, Competitive landscape, Research, Esophageal, Epidemiology, Esophageal cancer, Dietary supplement, Risk management, Pharmaceutical industry

The "US Esophageal Cancer Market and Competitive Landscape - 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Esophageal Cancer Market and Competitive Landscape - 2022" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive insights into Esophageal Cancer pipeline products, Esophageal Cancer epidemiology, Esophageal Cancer market valuations and forecast, Esophageal Cancer drugs sales and competitive landscape in the US.
  • Esophageal Cancer pipeline: Find out the products in clinical trials for the treatment of Esophageal Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Esophageal Cancer drugs: Identify key products marketed and prescribed for Esophageal Cancer in the US, including trade name, molecule name, and company
    Esophageal Cancer market valuations: Find out the market size for Esophageal Cancer drugs in 2021 in the US.
  • Find out how the market advanced from 2019 and forecast to 2027
    Esophageal Cancer drugs market share: Find out the market shares for key Esophageal Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Esophageal Cancer products